Expansion opportunities Recent distribution expansion for AGAMREE across Central Asia and the Caucasus alongside existing global approvals creates incremental sales opportunities through regional partnerships, distributor engagements, and managed care negotiations in new markets.

Strategic partnerships New and renewed partnerships, including Biomedica collaboration and North America licensing to Catalyst, indicate a continuing open approach to co-commercialization and out-licensing, suggesting targets for BD roles to identify additional licensees or exclusivity deals.

Clinical leadership Santhera’s focus on rare neuromuscular diseases and a dissociative steroid therapy positions the company to pursue investigator-initiated studies and payer-driven value demonstrations that can unlock coverage and patient access in specialty channels.

Executive cadence Upcoming leadership changes with a new CEO and CCO alongside ongoing board approvals signal a period of strategic realignment, offering opportunities to engage new executives on long-term commercial plans and market-entry strategies.

Financial readiness Significant funding and a mid-range revenue profile, plus a recent $40M investment, provide a runway for scaled commercialization, cross-border launches, and partnership-driven market access initiatives across geographies.